Short answer
Neurogene Inc. (NGNE) filed an 8-K current report with the SEC on April 20, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure). Board expanded to seven directors, adding internal executive Christine Mikail as Class II director through 2028 annual meeting.
Neurogene Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Board expanded to seven directors, adding internal executive Christine Mikail as Class II director through 2028 annual meeting
- Appointment strengthens board expertise in biotech strategy, business development, operations, finance, and transactions
- Mikail’s existing roles as President and CFO create tighter alignment between board oversight and company execution
- No additional director compensation, related-party transaction, or appointment arrangement disclosed
Item 7.01 · Regulation FD Disclosure
- Christina Shafer appointed Chief Commercial Officer, adding senior commercial leadership
- Christine Mikail appointed to the Board, filling a newly created vacancy
- Leadership changes may signal preparation for commercialization and broader governance oversight
- Press release dated April 20, 2026 provides additional appointment details
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Neurogene Inc. 8-K filings
Get the next NGNE 8-K as it lands
Follow NGNE for push alerts, or ask the research agent what this filing means.